21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
21.1 - Manufacture of basic pharmaceutical products
21.2 - Manufacture of pharmaceutical preparations and other pharmaceutical products
46 - Wholesale trade
52.1 - Warehousing and storage of goods
70.2 - Business and management consultancy activities
72 - Scientific research and development activities
73 - Advertising, market research and public relations
74 - Other professional, scientific and technical activities
78 - Employment activities
82 - Office administrative support activities and other business support services
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 22,1 | 14,2 | 18,5 | 30 |
EBITDA | 29 | 20,6 | 25,5 | 23,6 |
Short time liabilities | 49,6 | 57,6 | 60,2 | 4,6 |
Equity capital | 111,4 | 122,2 | 116,7 | -4,5 |
Operating profit (EBIT) | 22,2 | 14,2 | 18,2 | 28,3 |
Assets | 170,8 | 188,6 | 187,9 | -0,4 |
Net profit (loss) | 17,3 | 10,8 | 14,5 | 34,4 |
Cash | 8,3 | 8,7 | 2 | -77 |
Net income from sale | 248,4 | 276,9 | 308,2 | 11,3 |
Liabilities and provisions for liabilities | 59,4 | 66,4 | 71,2 | 7,2 |
Working assets | 130,1 | 147,5 | 142,3 | -3,5 |
Depreciation | 6,9 | 6,4 | 7,3 | 13,1 |
% | % | % | p.p. | |
Profitability of capital | 15,6 | 8,8 | 12,4 | 3,6 |
Equity capital to total assets | 65,2 | 64,8 | 62,1 | -2,7 |
Gross profit margin | 8,9 | 5,1 | 6 | 0,9 |
EBITDA Margin | 11,7 | 7,5 | 8,3 | 0,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 73 | 76 | 71 | -5 |
Current financial liquidity indicator | 2.4735066890716553 | 2.4207310676574707 | 2.2058892250061035 | -0,2 |
Net dept to EBITDA | -0.28627634048461914 | -0.41982126235961914 | -0.0780089721083641 | 0,3 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane